CoMentis Company
AmCyte develops encapsulated proliferated human islets for transplantation into patients with diabetes. The company specializes in adult stem cell research to treat diabetes with islet replacement therapy.
Investors
Headquarters:
United States
Number Of Exists:
N/A
Total Funding:
$107.5M
Founded Date:
2004
Employee Number:
51-100
Investment Stage:
N/A
Last Funding Type:
Series E
Investor Type:
N/A
Investors Number:
14
Technology:
Stem Cell
Funding Status:
Late Stage Venture
Industry:
Regenerative medicine